Bain Capital Life Sciences Investors, LLC bought $1.7M of OLMA
owner at Olema Pharmaceuticals, Inc.. 300,000 shares at an average of $5.76, traded Jan 8, 2025, filed Jan 13, 2025.
Score components
- +12Role10% owner
- +25Trade size$1.7M at market
- 0Relative to holdingsHoldings up 4.0%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-004870, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 8, 2025 | POpen-market purchase Common Stockindirect: See footnotes | +300,000 | $5.76 | $1.7M | 7,800,000 | Jan 13, 2025 |
| Jan 10, 2025 | JOther Common Stockindirect: See footnotes | -3,500,000 | - | - | 4,300,000 | Jan 13, 2025 |
| Jan 10, 2025 | JOther Pre-Funded Warrant (right to buy)derivativeindirect: See footnotes | +3,500,000 | - | - | 3,500,000 | Jan 13, 2025 |
Related signals
Other insiders at Olema Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 48Moderate | OLMAbuy Olema Pharmaceuticals, Inc. | G. Walmsley Graham director | $4.7M 700,761 shares | - | |
| 75Notable | Olema Pharmaceuticals, Inc. | G. Walmsley Graham director | $4.7M 700,761 shares | -100% | |
| 55Moderate | OLMAbuy Olema Pharmaceuticals, Inc. | G. Walmsley Graham director | $4.7M 700,761 shares | +99% | |
| 75Notable | Olema Pharmaceuticals, Inc. | G. Walmsley Graham director | $4.7M 700,761 shares | -100% | |
| 75Notable | Olema Pharmaceuticals, Inc. | Sean Bohen PRESIDENT AND CEO | $986k 109,502 shares | -31% | |
| 41Moderate | Olema Pharmaceuticals, Inc. | Cyrus Harmon director | $148k 16,393 shares | -2% | |
| 44Moderate | Olema Pharmaceuticals, Inc. | Shane William Charles Kovacs CH. OPERATING & FINANCIAL OFF. | $317k 35,159 shares | -6% | |
| 43Moderate | Olema Pharmaceuticals, Inc. | David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | $235k 26,066 shares | -4% | |
| 48Moderate | Olema Pharmaceuticals, Inc. | Naseem Zojwalla CHIEF MEDICAL OFFICER | $250k 27,805 shares | -19% | |
| 60Notable | OLMAsell Olema Pharmaceuticals, Inc. | G. Walmsley Graham director | $17M 1,175,000 shares | -84% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.